
Progress at last against RSV
The approval of two vaccines and a monoclonal antibody that target respiratory syncytial virus could shift the tide on the prevention and treatment of infection with this virus.
The approval of two vaccines and a monoclonal antibody that target respiratory syncytial virus could shift the tide on the prevention and treatment of infection with this virus.
As the search for new and better treatments for Alzheimer’s disease continues, a phase 1 proof-of-concept study evaluating senolytic therapy breaks new ground.